Early preclinical research reported the oral administration of Bifidobacterium in enhancing anti-tumor immune responses by eliciting DCs for promoting cytotoxic roles of CD8+ T-cells, aiding in ICIs effectivity (24). This evidence concerns the gene CD8A and neoplasm.